Rome

• A Phase 3 Study to Evaluate Efficacy and Safety of a Single Dose of Exa-cel in Subjects with Severe Sickle Cell Disease, βS/βC Genotype Pending
  2023-503247-34-00 5 Sickle cell anaemia
• Progression under Olaparib: a randomized phaSE II trIal with docetaxel or carboplatin-docetaxel DOublet in mCRPC patieNts Pending
  2023-503676-25-01 4 prostate cancer
• MITO CERV4: Single arm phase II study on Pembrolizumab in pre neoplastic high grade HPV-related vulvar and cervical lesions Pending
  2023-504035-40-00 4 Patients with pre neoplastic high grade HPV-related vulvar and cervica
• Oxytocin for drug relapse prevention Pending
  2023-504518-31-01 4 substance use disorder
• Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy Pending
  2023-505750-17-00 4 Neovascular age-related macular degeneration
• A Study to Test the Safety, Tolerability, and Efficacy of an Antibody, REGN7999, Injected Under the Skin for the Treatment of Iron Overload … Pending
  2023-508604-37-00 4 Non-transfusion dependent beta-thalassemia (NTDT), Beta-thalassemia Re
• A study to investigate efficacy of RP2 with nivolumab compared to ipilimumab with nivolumab in adult patients with advanced uveal melanoma n … Pending
  2023-508784-68-00 10 metastatic uveal melanoma
• IntReALL BCP 2020 – International Study for Treatment of Childhood Relapsed Precursor B-cell ALL 2020 Pending
  2023-509392-17-00 5 Relapsed Acute Lymphoblastic Leukemia (ALL)
• Study of Oral Weekly GS-1720 and GS-4182 Versus Biktarvy in People With HIV-1 Who Are Virologically Suppressed Pending
  2024-511054-50-00 10 HIV-1 Infection
• An Open-Label Extension Study to Evaluate the Long-term Safety and Efficacy of BMN 351 in Participants with Duchenne Muscular Dystrophy Pending
  2024-511656-41-00 4 Duchenne Muscular Dystrophy
• A trial to learn how well Dato-DXd and rilvegostomig work and how safe they are in participants with stage I adenocarcinoma non-small cell l … Pending
  2024-512195-35-00 5 Stage I adenocarcinoma non-small cell lung cancer (NSCLC) with ctDNA-p
• A Phase 1/2a Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARO-DM1 in Subjects With … Pending
  2024-513579-42-00 7 Type 1 Myotonic Dystrophy
• Extension Study of ACT-EARLY Pending
  2024-513676-18-00 5 Transthyretin Amyloidosis
• SIOP PNET 5 medulloblastoma Pending
  2024-513724-42-00 10 Medulloblastoma
• DORAL Pending
  2024-513941-35-00 9 HIV Disease
• Temporal kinetics of antibody and cellular response markers and relative impact of revaccination in patients recovered from COVID-19 after t … Pending
  2024-514071-17-00 6 Covid-19 infection
• A study to find an efficacious and safe dose of CHF10067 (zampilimab) in participants with idiopathic pulmonary fibrosis Pending
  2024-514246-37-00 4 Idiopathic pulmonary fibrosis (IPF)
• A 52 week study in which neither Sponsor or participant know the treatment assigned to subjects to compare the experimental drug (CHF 5993) … Pending
  2024-514248-95-00 5 Uncontrolled Asthma
• PIrfenidone to prevent fibrOsis in ARDS. A RaNdomizEd controllEd tRial - PIONEER Pending
  2024-514355-16-01 5 Acute Respiratory Distress Syndrome (ARDS)
• A randomized phase II study of Pembrolizumab (MK-3475) as maintainance therapy in patients with unresectable stage III non-small cell lung … Pending
  2024-514701-57-01 4 non Small Cell Lung Cancer
• A Phase 2 Study of NEU-411 in Companion Diagnostic-Positive Participants with Early Parkinson’s Disease Pending
  2024-515448-22-00 4 Parkinson
• Long-term impact of GBCAs on motor and cognitive function following repeated Contrast-Enhanced MRI—ODYSSEY Pending
  2024-515462-14-00 6 Long term potential effect of repeated exposure to either a linear or
• A Clinical Trial to Investigate the Efficacy, Safety and Pharmacokinetics of Elsunersen in Children Pending
  2024-515598-82-00 5 Voltage-gated sodium channel type II alpha subunit (SCN2A) development
• Vitamin D as add-on treatment option of pneumonia and sepsis in elderly subjects (TreatViD) Pending
  2024-515978-27-00 11 Sepsis

Showing 25–48 of 2,096 trials